– Dr. Jarrod P. Holmes, a prominent breast cancer vaccine expert to lead the study out of St. Joseph Health-Sonoma County Berkeley, CA and Vancouver, BC – August 17, 2016 – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSXV: BCT) (OTCQB: BCTXF) is pleased to announce that Dr. Jarrod P. Holmes, a Board Certified Oncologist …
BriaCell Therapeutics Corp. (OTCQB:BCTXF)(TSX VENTURE:BCT) (“BriaCell”, the “Company”, or “BCT”) announced today that it intends to complete a non-brokered private placement (the “Offering”) of units of the Company (the “Units”) at a price of $0.20 per Unit for aggregate gross proceeds of up to $1,500,000. Under the Offering, each Unit shall consist of one common …
BERKELEY, CA and VANCOUVER, BC–(Marketwired – May 18, 2016) – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX VENTURE: BCT) (OTCQB: BCTXF) is pleased to announce that it has signed a definitive agreement with Cancer Insight, LLC, a cancer-vaccine focused clinical research organization (CRO), to initiate Phase I/IIa clinical studies and regulatory filings for BriaVax™, …
Berkeley, CA and Vancouver, BC – Tuesday May 10, 2016 – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSXV: BCT) (OTCQB: BCTXF) today announced a change to its board of directors. BriaCell is pleased to welcome the appointment of Mr. Martin Schmieg to its Board of Directors. Mr. Schmieg, with 35 years of business experience, …
Berkeley, CA and Vancouver, BC – May 3, 2016 – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSXV: BCT) (OTCQB: BCTXF) is pleased to announce that the Company has completed both its previously announced brokered and non-brokered private placements of units totaling gross proceeds of C$1,275,000. BriaCell intends to use the proceeds from the financings …
BriaCell Therapeutics Corp. (TSX VENTURE:BCT)(OTCQB:BCTXF) (“BriaCell”, the “Company”, or “BCT”) announced today that it intends to complete a non-brokered private placement (the “Offering”) of units of the Company (the “Units”) at a price of $0.20 per Unit for aggregate gross proceeds of up to C$600,000. The Offering is in addition to the Company’s proposed strategic …
Berkeley, CA and Vancouver, BC – April 22, 2016 – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSXV: BCT) (OTCQB: BCTXF) is very pleased to announce that it has entered into an agreement with a leading US biotechnology fund for an investment of C$650,000. The subscription agreement of units (“Units”) is priced at C$0.19, each …
– Data Presentation at American Association for Cancer Research (AACR) Annual Meeting 2016 – Berkeley, CA and Vancouver, BC – April 12, 2016 – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSXV: BCT) (OTCQB: BCTXF) is very pleased to announce that it has filed a provisional patent application with the U.S. Patent and Trademark Office …
BERKELEY, CA and VANCOUVER, BC–(Marketwired – April 05, 2016) – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”)(TSX VENTURE: BCT) (BCTXF) is very pleased to provide an update in regard to the planned timing of its Phase I/II clinical trial for up to 24 late-stage cancer patients. BriaCell has spent a great deal of time and …
BERKELEY, CA and VANCOUVER, BC–(Marketwired – March 29, 2016) – BriaCell Therapeutics Corp.(“BriaCell” or the “Company”)(TSX VENTURE: BCT) (BCTXF) is very pleased to announce that it has discovered a gene signature potentially explaining why its BriaVax™ cancer vaccine was exceptionally efficacious in a clinical trial subject with stage IV breast cancer. Data will be presented at the Annual …